img

Global and United States Non Alcoholic Steatohepatitis Treatment Market Report & Forecast 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and United States Non Alcoholic Steatohepatitis Treatment Market Report & Forecast 2024-2034

Market Analysis and InsightsGlobal and United States Non Alcoholic Steatohepatitis Treatment Market
This report focuses on global and United States Non Alcoholic Steatohepatitis Treatment market, also covers the segmentation data of other regions in regional level and county level.
The global Non Alcoholic Steatohepatitis Treatment revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In United States the Non Alcoholic Steatohepatitis Treatment revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Non Alcoholic Steatohepatitis Treatment include AstraZeneca Plc., Tobira Therapeutics Inc., Galmed Pharmaceuticals, Genfit SA, Zydus Cadila, Bristol Myers Squibb, Gilead Science, Conatus Pharmaceuticals Inc. and Novo Nordisk A/S, etc. The global five biggest players hold a share of % in 2024.
Global Non Alcoholic Steatohepatitis Treatment Scope and Market Size
Non Alcoholic Steatohepatitis Treatment market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Non Alcoholic Steatohepatitis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Non Alcoholic Steatohepatitis Treatment market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.



By Company


AstraZeneca Plc.
Tobira Therapeutics Inc.
Galmed Pharmaceuticals
Genfit SA
Zydus Cadila
Bristol Myers Squibb
Gilead Science
Conatus Pharmaceuticals Inc.
Novo Nordisk A/S
Immuron Ltd.
Raptor Pharmaceutical Corporation
Inventiva Pharma
NGM Biopharmaceuticals Inc.
Galectin Therapeutics Inc.
Madrigal Pharmaceuticals
Gemphire Therapeutics
Segment by Type
Vitamin E And Pioglitazone
Ocaliva
Elafibranor
Obeticholic Acid

Segment by Application


Hospital Pharmacies
Retail And Specialty Pharmacies
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Non Alcoholic Steatohepatitis Treatment definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Non Alcoholic Steatohepatitis Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Non Alcoholic Steatohepatitis Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non Alcoholic Steatohepatitis Treatment sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 Non Alcoholic Steatohepatitis Treatment Product Introduction
1.2 Global Non Alcoholic Steatohepatitis Treatment Outlook 2018 VS 2024 VS 2034
1.2.1 Global Non Alcoholic Steatohepatitis Treatment Sales in US$ Million for the Year 2018-2034
1.2.2 Global Non Alcoholic Steatohepatitis Treatment Sales in Volume for the Year 2018-2034
1.3 United States Non Alcoholic Steatohepatitis Treatment Outlook 2018 VS 2024 VS 2034
1.3.1 United States Non Alcoholic Steatohepatitis Treatment Sales in US$ Million for the Year 2018-2034
1.3.2 United States Non Alcoholic Steatohepatitis Treatment Sales in Volume for the Year 2018-2034
1.4 Non Alcoholic Steatohepatitis Treatment Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.4.1 The Market Share of United States Non Alcoholic Steatohepatitis Treatment in Global, 2018 VS 2024 VS 2034
1.4.2 The Growth Rate of Non Alcoholic Steatohepatitis Treatment Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.5 Non Alcoholic Steatohepatitis Treatment Market Dynamics
1.5.1 Non Alcoholic Steatohepatitis Treatment Industry Trends
1.5.2 Non Alcoholic Steatohepatitis Treatment Market Drivers
1.5.3 Non Alcoholic Steatohepatitis Treatment Market Challenges
1.5.4 Non Alcoholic Steatohepatitis Treatment Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 Non Alcoholic Steatohepatitis Treatment by Type
2.1 Non Alcoholic Steatohepatitis Treatment Market Segment by Type
2.1.1 Vitamin E And Pioglitazone
2.1.2 Ocaliva
2.1.3 Elafibranor
2.1.4 Obeticholic Acid
2.2 Global Non Alcoholic Steatohepatitis Treatment Market Size by Type
2.2.1 Global Non Alcoholic Steatohepatitis Treatment Sales in Value, by Type (2018, 2024 & 2034)
2.2.2 Global Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Type (2018, 2024 & 2034)
2.2.3 Global Non Alcoholic Steatohepatitis Treatment Average Selling Price (ASP) by Type (2018, 2024 & 2034)
2.3 United States Non Alcoholic Steatohepatitis Treatment Market Size by Type
2.3.1 United States Non Alcoholic Steatohepatitis Treatment Sales in Value, by Type (2018, 2024 & 2034)
2.3.2 United States Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Type (2018, 2024 & 2034)
2.3.3 United States Non Alcoholic Steatohepatitis Treatment Average Selling Price (ASP) by Type (2018, 2024 & 2034)
3 Non Alcoholic Steatohepatitis Treatment by Application
3.1 Non Alcoholic Steatohepatitis Treatment Market Segment by Application
3.1.1 Hospital Pharmacies
3.1.2 Retail And Specialty Pharmacies
3.2 Global Non Alcoholic Steatohepatitis Treatment Market Size by Application
3.2.1 Global Non Alcoholic Steatohepatitis Treatment Sales in Value, by Application (2018, 2024 & 2034)
3.2.2 Global Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 Global Non Alcoholic Steatohepatitis Treatment Average Selling Price (ASP) by Application (2018, 2024 & 2034)
3.3 United States Non Alcoholic Steatohepatitis Treatment Market Size by Application
3.3.1 United States Non Alcoholic Steatohepatitis Treatment Sales in Value, by Application (2018, 2024 & 2034)
3.3.2 United States Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 United States Non Alcoholic Steatohepatitis Treatment Average Selling Price (ASP) by Application (2018, 2024 & 2034)
4 Global Non Alcoholic Steatohepatitis Treatment Competitor Landscape by Company
4.1 Global Non Alcoholic Steatohepatitis Treatment Market Size by Company
4.1.1 Global Key Manufacturers of Non Alcoholic Steatohepatitis Treatment, Ranked by Revenue (2024)
4.1.2 Global Non Alcoholic Steatohepatitis Treatment Revenue by Manufacturer (2018-2023)
4.1.3 Global Non Alcoholic Steatohepatitis Treatment Sales by Manufacturer (2018-2023)
4.1.4 Global Non Alcoholic Steatohepatitis Treatment Price by Manufacturer (2018-2023)
4.2 Global Non Alcoholic Steatohepatitis Treatment Concentration Ratio (CR)
4.2.1 Non Alcoholic Steatohepatitis Treatment Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Non Alcoholic Steatohepatitis Treatment in 2024
4.2.3 Global Non Alcoholic Steatohepatitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of Non Alcoholic Steatohepatitis Treatment, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of Non Alcoholic Steatohepatitis Treatment, Product Offered and Application
4.5 Global Key Manufacturers of Non Alcoholic Steatohepatitis Treatment, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 United States Non Alcoholic Steatohepatitis Treatment Market Size by Company
4.7.1 Key Players of Non Alcoholic Steatohepatitis Treatment in United States, Ranked by Revenue (2024)
4.7.2 United States Non Alcoholic Steatohepatitis Treatment Revenue by Players (2018-2023)
4.7.3 United States Non Alcoholic Steatohepatitis Treatment Sales by Players (2018-2023)
5 Global Non Alcoholic Steatohepatitis Treatment Market Size by Region
5.1 Global Non Alcoholic Steatohepatitis Treatment Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global Non Alcoholic Steatohepatitis Treatment Market Size in Volume by Region (2018-2034)
5.2.1 Global Non Alcoholic Steatohepatitis Treatment Sales in Volume by Region: 2018-2023
5.2.2 Global Non Alcoholic Steatohepatitis Treatment Sales in Volume Forecast by Region (2024-2034)
5.3 Global Non Alcoholic Steatohepatitis Treatment Market Size in Value by Region (2018-2034)
5.3.1 Global Non Alcoholic Steatohepatitis Treatment Sales in Value by Region: 2018-2023
5.3.2 Global Non Alcoholic Steatohepatitis Treatment Sales in Value by Region: 2024-2034
6 Americas
6.1 Americas Non Alcoholic Steatohepatitis Treatment Market Size YoY Growth 2018-2034
6.2 Americas Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Type (2018, 2024 & 2034)
6.3 Americas Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Application (2018, 2024 & 2034)
6.4 Americas Non Alcoholic Steatohepatitis Treatment Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 Americas Non Alcoholic Steatohepatitis Treatment Sales in Value by Country (2018, 2024 & 2034)
6.4.2 Americas Non Alcoholic Steatohepatitis Treatment Sales in Volume by Country (2018, 2024 & 2034)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA Non Alcoholic Steatohepatitis Treatment Market Size YoY Growth 2018-2034
7.2 EMEA Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Type (2018, 2024 & 2034)
7.3 EMEA Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Application (2018, 2024 & 2034)
7.4 EMEA Non Alcoholic Steatohepatitis Treatment Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 EMEA Non Alcoholic Steatohepatitis Treatment Sales in Value by Country (2018, 2024 & 2034)
7.4.2 EMEA Non Alcoholic Steatohepatitis Treatment Sales in Volume by Country (2018, 2024 & 2034)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China Non Alcoholic Steatohepatitis Treatment Market Size YoY Growth 2018-2034
8.2 China Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Type (2018, 2024 & 2034)
8.3 China Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Application (2018, 2024 & 2034)
9 APAC
9.1 APAC Non Alcoholic Steatohepatitis Treatment Market Size YoY Growth 2018-2034
9.2 APAC Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Type (2018, 2024 & 2034)
9.3 APAC Non Alcoholic Steatohepatitis Treatment Sales in Volume, by Application (2018, 2024 & 2034)
9.4 APAC Non Alcoholic Steatohepatitis Treatment Market Facts & Figures by Region (2018, 2024 & 2034)
9.4.1 APAC Non Alcoholic Steatohepatitis Treatment Sales in Value by Region (2018, 2024 & 2034)
9.4.2 APAC Non Alcoholic Steatohepatitis Treatment Sales in Volume by Region (2018, 2024 & 2034)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 AstraZeneca Plc.
10.1.1 AstraZeneca Plc. Company Information
10.1.2 AstraZeneca Plc. Description and Business Overview
10.1.3 AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.1.4 AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Products Offered
10.1.5 AstraZeneca Plc. Recent Development
10.2 Tobira Therapeutics Inc.
10.2.1 Tobira Therapeutics Inc. Company Information
10.2.2 Tobira Therapeutics Inc. Description and Business Overview
10.2.3 Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Products Offered
10.2.5 Tobira Therapeutics Inc. Recent Development
10.3 Galmed Pharmaceuticals
10.3.1 Galmed Pharmaceuticals Company Information
10.3.2 Galmed Pharmaceuticals Description and Business Overview
10.3.3 Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Products Offered
10.3.5 Galmed Pharmaceuticals Recent Development
10.4 Genfit SA
10.4.1 Genfit SA Company Information
10.4.2 Genfit SA Description and Business Overview
10.4.3 Genfit SA Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Genfit SA Non Alcoholic Steatohepatitis Treatment Products Offered
10.4.5 Genfit SA Recent Development
10.5 Zydus Cadila
10.5.1 Zydus Cadila Company Information
10.5.2 Zydus Cadila Description and Business Overview
10.5.3 Zydus Cadila Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Zydus Cadila Non Alcoholic Steatohepatitis Treatment Products Offered
10.5.5 Zydus Cadila Recent Development
10.6 Bristol Myers Squibb
10.6.1 Bristol Myers Squibb Company Information
10.6.2 Bristol Myers Squibb Description and Business Overview
10.6.3 Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Products Offered
10.6.5 Bristol Myers Squibb Recent Development
10.7 Gilead Science
10.7.1 Gilead Science Company Information
10.7.2 Gilead Science Description and Business Overview
10.7.3 Gilead Science Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Gilead Science Non Alcoholic Steatohepatitis Treatment Products Offered
10.7.5 Gilead Science Recent Development
10.8 Conatus Pharmaceuticals Inc.
10.8.1 Conatus Pharmaceuticals Inc. Company Information
10.8.2 Conatus Pharmaceuticals Inc. Description and Business Overview
10.8.3 Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Products Offered
10.8.5 Conatus Pharmaceuticals Inc. Recent Development
10.9 Novo Nordisk A/S
10.9.1 Novo Nordisk A/S Company Information
10.9.2 Novo Nordisk A/S Description and Business Overview
10.9.3 Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Products Offered
10.9.5 Novo Nordisk A/S Recent Development
10.10 Immuron Ltd.
10.10.1 Immuron Ltd. Company Information
10.10.2 Immuron Ltd. Description and Business Overview
10.10.3 Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Products Offered
10.10.5 Immuron Ltd. Recent Development
10.11 Raptor Pharmaceutical Corporation
10.11.1 Raptor Pharmaceutical Corporation Company Information
10.11.2 Raptor Pharmaceutical Corporation Description and Business Overview
10.11.3 Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Products Offered
10.11.5 Raptor Pharmaceutical Corporation Recent Development
10.12 Inventiva Pharma
10.12.1 Inventiva Pharma Company Information
10.12.2 Inventiva Pharma Description and Business Overview
10.12.3 Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Products Offered
10.12.5 Inventiva Pharma Recent Development
10.13 NGM Biopharmaceuticals Inc.
10.13.1 NGM Biopharmaceuticals Inc. Company Information
10.13.2 NGM Biopharmaceuticals Inc. Description and Business Overview
10.13.3 NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.13.4 NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Products Offered
10.13.5 NGM Biopharmaceuticals Inc. Recent Development
10.14 Galectin Therapeutics Inc.
10.14.1 Galectin Therapeutics Inc. Company Information
10.14.2 Galectin Therapeutics Inc. Description and Business Overview
10.14.3 Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Products Offered
10.14.5 Galectin Therapeutics Inc. Recent Development
10.15 Madrigal Pharmaceuticals
10.15.1 Madrigal Pharmaceuticals Company Information
10.15.2 Madrigal Pharmaceuticals Description and Business Overview
10.15.3 Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Products Offered
10.15.5 Madrigal Pharmaceuticals Recent Development
10.16 Gemphire Therapeutics
10.16.1 Gemphire Therapeutics Company Information
10.16.2 Gemphire Therapeutics Description and Business Overview
10.16.3 Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Products Offered
10.16.5 Gemphire Therapeutics Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 Non Alcoholic Steatohepatitis Treatment Industry Chain Analysis
11.2 Non Alcoholic Steatohepatitis Treatment Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 Non Alcoholic Steatohepatitis Treatment Production Mode & Process
11.4 Non Alcoholic Steatohepatitis Treatment Sales and Marketing
11.4.1 Non Alcoholic Steatohepatitis Treatment Sales Channels
11.4.2 Non Alcoholic Steatohepatitis Treatment Distributors
11.5 Non Alcoholic Steatohepatitis Treatment Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. Non Alcoholic Steatohepatitis Treatment CAGR in Value, United States VS Global, 2018 VS 2024 VS 2034
Table 2. Non Alcoholic Steatohepatitis Treatment Market Trends
Table 3. Non Alcoholic Steatohepatitis Treatment Market Drivers
Table 4. Non Alcoholic Steatohepatitis Treatment Market Challenges
Table 5. Non Alcoholic Steatohepatitis Treatment Market Restraints
Table 6. Global Non Alcoholic Steatohepatitis Treatment Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. United States Non Alcoholic Steatohepatitis Treatment Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Non Alcoholic Steatohepatitis Treatment Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. United States Non Alcoholic Steatohepatitis Treatment Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Manufacturers of Non Alcoholic Steatohepatitis Treatment, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global Non Alcoholic Steatohepatitis Treatment Revenue by Manufacturer, (US$ Million), 2018-2023
Table 12. Global Non Alcoholic Steatohepatitis Treatment Revenue Share by Manufacturer, 2018-2023
Table 13. Global Non Alcoholic Steatohepatitis Treatment Sales by Manufacturer, (K Units), 2018-2023
Table 14. Global Non Alcoholic Steatohepatitis Treatment Sales Share by Manufacturer, 2018-2023
Table 15. Global Non Alcoholic Steatohepatitis Treatment Price by Manufacturer (2018-2023) & (US$/Unit)
Table 16. Global Non Alcoholic Steatohepatitis Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Non Alcoholic Steatohepatitis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non Alcoholic Steatohepatitis Treatment as of 2024)
Table 18. Global Key Manufacturers of Non Alcoholic Steatohepatitis Treatment, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of Non Alcoholic Steatohepatitis Treatment, Product Offered and Application
Table 20. Global Key Manufacturers of Non Alcoholic Steatohepatitis Treatment, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of Non Alcoholic Steatohepatitis Treatment in United States, Ranked by Revenue (2024) & (US$ million)
Table 23. United States Non Alcoholic Steatohepatitis Treatment Revenue by Players, (US$ Million), (2018-2023)
Table 24. United States Non Alcoholic Steatohepatitis Treatment Revenue Share by Players, (2018-2023)
Table 25. United States Non Alcoholic Steatohepatitis Treatment Sales by Players, (K Units), (2018-2023)
Table 26. United States Non Alcoholic Steatohepatitis Treatment Sales Share by Players, (2018-2023)
Table 27. Global Non Alcoholic Steatohepatitis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 28. Global Non Alcoholic Steatohepatitis Treatment Sales in Volume by Region (2018-2023) & (K Units)
Table 29. Global Non Alcoholic Steatohepatitis Treatment Sales in Volume Forecast by Region (2024-2034) & (K Units)
Table 30. Global Non Alcoholic Steatohepatitis Treatment Sales in Value by Region (2018-2023) & (US$ Million)
Table 31. Global Non Alcoholic Steatohepatitis Treatment Sales in Value Forecast by Region (2024-2034) & (US$ Million)
Table 32. Americas Non Alcoholic Steatohepatitis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 33. Americas Non Alcoholic Steatohepatitis Treatment Sales in Value by Country (2018-2023) & (US$ Million)
Table 34. Americas Non Alcoholic Steatohepatitis Treatment Sales in Value by Country (2024-2034) & (US$ Million)
Table 35. Americas Non Alcoholic Steatohepatitis Treatment Sales in Volume by Country (2018-2023) & (K Units)
Table 36. Americas Non Alcoholic Steatohepatitis Treatment Sales in Volume by Country (2024-2034) & (K Units)
Table 37. EMEA Non Alcoholic Steatohepatitis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. EMEA Non Alcoholic Steatohepatitis Treatment Sales in Value by Country (2018-2023) & (US$ Million)
Table 39. EMEA Non Alcoholic Steatohepatitis Treatment Sales in Value by Country (2024-2034) & (US$ Million)
Table 40. EMEA Non Alcoholic Steatohepatitis Treatment Sales in Volume by Country (2018-2023) & (K Units)
Table 41. EMEA Non Alcoholic Steatohepatitis Treatment Sales in Volume by Country (2024-2034) & (K Units)
Table 42. APAC Non Alcoholic Steatohepatitis Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 43. APAC Non Alcoholic Steatohepatitis Treatment Sales in Value by Country (2018-2023) & (US$ Million)
Table 44. APAC Non Alcoholic Steatohepatitis Treatment Sales in Value by Country (2024-2034) & (US$ Million)
Table 45. APAC Non Alcoholic Steatohepatitis Treatment Sales in Volume by Country (2018-2023) & (K Units)
Table 46. APAC Non Alcoholic Steatohepatitis Treatment Sales in Volume by Country (2024-2034) & (K Units)
Table 47. AstraZeneca Plc. Company Information
Table 48. AstraZeneca Plc. Description and Business Overview
Table 49. AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 50. AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Product
Table 51. AstraZeneca Plc. Recent Development
Table 52. Tobira Therapeutics Inc. Company Information
Table 53. Tobira Therapeutics Inc. Description and Business Overview
Table 54. Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 55. Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Product
Table 56. Tobira Therapeutics Inc. Recent Development
Table 57. Galmed Pharmaceuticals Company Information
Table 58. Galmed Pharmaceuticals Description and Business Overview
Table 59. Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 60. Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Product
Table 61. Galmed Pharmaceuticals Recent Development
Table 62. Genfit SA Company Information
Table 63. Genfit SA Description and Business Overview
Table 64. Genfit SA Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 65. Genfit SA Non Alcoholic Steatohepatitis Treatment Product
Table 66. Genfit SA Recent Development
Table 67. Zydus Cadila Company Information
Table 68. Zydus Cadila Description and Business Overview
Table 69. Zydus Cadila Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 70. Zydus Cadila Non Alcoholic Steatohepatitis Treatment Product
Table 71. Zydus Cadila Recent Development
Table 72. Bristol Myers Squibb Company Information
Table 73. Bristol Myers Squibb Description and Business Overview
Table 74. Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 75. Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Product
Table 76. Bristol Myers Squibb Recent Development
Table 77. Gilead Science Company Information
Table 78. Gilead Science Description and Business Overview
Table 79. Gilead Science Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 80. Gilead Science Non Alcoholic Steatohepatitis Treatment Product
Table 81. Gilead Science Recent Development
Table 82. Conatus Pharmaceuticals Inc. Company Information
Table 83. Conatus Pharmaceuticals Inc. Description and Business Overview
Table 84. Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Product
Table 86. Conatus Pharmaceuticals Inc. Recent Development
Table 87. Novo Nordisk A/S Company Information
Table 88. Novo Nordisk A/S Description and Business Overview
Table 89. Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Product
Table 91. Novo Nordisk A/S Recent Development
Table 92. Immuron Ltd. Company Information
Table 93. Immuron Ltd. Description and Business Overview
Table 94. Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Product
Table 96. Immuron Ltd. Recent Development
Table 97. Raptor Pharmaceutical Corporation Company Information
Table 98. Raptor Pharmaceutical Corporation Description and Business Overview
Table 99. Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Product
Table 101. Raptor Pharmaceutical Corporation Recent Development
Table 102. Inventiva Pharma Company Information
Table 103. Inventiva Pharma Description and Business Overview
Table 104. Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Product
Table 106. Inventiva Pharma Recent Development
Table 107. NGM Biopharmaceuticals Inc. Company Information
Table 108. NGM Biopharmaceuticals Inc. Description and Business Overview
Table 109. NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Product
Table 111. NGM Biopharmaceuticals Inc. Recent Development
Table 112. Galectin Therapeutics Inc. Company Information
Table 113. Galectin Therapeutics Inc. Description and Business Overview
Table 114. Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Product
Table 116. Galectin Therapeutics Inc. Recent Development
Table 117. Madrigal Pharmaceuticals Company Information
Table 118. Madrigal Pharmaceuticals Description and Business Overview
Table 119. Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Product
Table 121. Madrigal Pharmaceuticals Recent Development
Table 122. Gemphire Therapeutics Company Information
Table 123. Gemphire Therapeutics Description and Business Overview
Table 124. Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Product
Table 126. Gemphire Therapeutics Recent Development
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Non Alcoholic Steatohepatitis Treatment Customers List
Table 130. Non Alcoholic Steatohepatitis Treatment Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Non Alcoholic Steatohepatitis Treatment Product Picture
Figure 2. Global Non Alcoholic Steatohepatitis Treatment Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global Non Alcoholic Steatohepatitis Treatment Market Size 2018-2034 (US$ Million)
Figure 4. Global Non Alcoholic Steatohepatitis Treatment Sales 2018-2034 (K Units)
Figure 5. United States Non Alcoholic Steatohepatitis Treatment Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 6. United States Non Alcoholic Steatohepatitis Treatment Market Size 2018-2034 (US$ Million)
Figure 7. United States Non Alcoholic Steatohepatitis Treatment Sales 2018-2034 (K Units)
Figure 8. United States Non Alcoholic Steatohepatitis Treatment Market Share in Global, in Value (US$ Million) 2018-2034
Figure 9. United States Non Alcoholic Steatohepatitis Treatment Market Share in Global, in Volume (K Units) 2018-2034
Figure 10. Non Alcoholic Steatohepatitis Treatment Report Years Considered
Figure 11. Product Picture of Vitamin E And Pioglitazone
Figure 12. Product Picture of Ocaliva
Figure 13. Product Picture of Elafibranor
Figure 14. Product Picture of Obeticholic Acid
Figure 15. Global Non Alcoholic Steatohepatitis Treatment Market Share by Type in 2024 & 2034
Figure 16. Global Non Alcoholic Steatohepatitis Treatment Sales in Value by Type (2018-2034) & (US$ Million)
Figure 17. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share in Value by Type (2018-2034)
Figure 18. Global Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2034) & (K Units)
Figure 19. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Type (2018-2034)
Figure 20. Global Non Alcoholic Steatohepatitis Treatment Price by Type (2018-2034) & (US$/Unit)
Figure 21. United States Non Alcoholic Steatohepatitis Treatment Market Share by Type in 2024 & 2034
Figure 22. United States Non Alcoholic Steatohepatitis Treatment Sales in Value by Type (2018-2034) & (US$ Million)
Figure 23. United States Non Alcoholic Steatohepatitis Treatment Sales Market Share in Value by Type (2018-2034)
Figure 24. United States Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2034) & (K Units)
Figure 25. United States Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Type (2018-2034)
Figure 26. United States Non Alcoholic Steatohepatitis Treatment Price by Type (2018-2034) & (US$/Unit)
Figure 27. Product Picture of Hospital Pharmacies
Figure 28. Product Picture of Retail And Specialty Pharmacies
Figure 29. Global Non Alcoholic Steatohepatitis Treatment Market Share by Application in 2024 & 2034
Figure 30. Global Non Alcoholic Steatohepatitis Treatment Sales in Value by Application (2018-2034) & (US$ Million)
Figure 31. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share in Value by Application (2018-2034)
Figure 32. Global Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2034) & (K Units)
Figure 33. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Application (2018-2034)
Figure 34. Global Non Alcoholic Steatohepatitis Treatment Price by Application (2018-2034) & (US$/Unit)
Figure 35. United States Non Alcoholic Steatohepatitis Treatment Market Share by Application in 2024 & 2034
Figure 36. United States Non Alcoholic Steatohepatitis Treatment Sales in Value by Application (2018-2034) & (US$ Million)
Figure 37. United States Non Alcoholic Steatohepatitis Treatment Sales Market Share in Value by Application (2018-2034)
Figure 38. United States Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2034) & (K Units)
Figure 39. United States Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Application (2018-2034)
Figure 40. United States Non Alcoholic Steatohepatitis Treatment Price by Application (2018-2034) & (US$/Unit)
Figure 41. Americas Non Alcoholic Steatohepatitis Treatment Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 42. Americas Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 43. Americas Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2034) & (K Units)
Figure 44. Americas Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Type (2018-2034)
Figure 45. Americas Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2034) & (K Units)
Figure 46. Americas Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Application (2018-2034)
Figure 47. United States Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 48. Canada Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 49. Mexico Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 50. Brazil Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 51. EMEA Non Alcoholic Steatohepatitis Treatment Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 52. EMEA Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 53. EMEA Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2034) & (K Units)
Figure 54. EMEA Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Type (2018-2034)
Figure 55. EMEA Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2034) & (K Units)
Figure 56. EMEA Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Application (2018-2034)
Figure 57. Europe Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 58. Middle East Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 59. Africa Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 60. China Non Alcoholic Steatohepatitis Treatment Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 61. China Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 62. China Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2034) & (K Units)
Figure 63. China Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Type (2018-2034)
Figure 64. China Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2034) & (K Units)
Figure 65. China Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Application (2018-2034)
Figure 66. APAC Non Alcoholic Steatohepatitis Treatment Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 67. APAC Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 68. APAC Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2034) & (K Units)
Figure 69. APAC Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Type (2018-2034)
Figure 70. APAC Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2034) & (K Units)
Figure 71. APAC Non Alcoholic Steatohepatitis Treatment Sales Market Share in Volume by Application (2018-2034)
Figure 72. Japan Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 73. South Korea Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 74. China Taiwan Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 76. India Non Alcoholic Steatohepatitis Treatment Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 77. Non Alcoholic Steatohepatitis Treatment Value Chain
Figure 78. Non Alcoholic Steatohepatitis Treatment Production Process
Figure 79. Channels of Distribution
Figure 80. Distributors Profiles
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries